NVTA vs. OPGN, BGLC, SNES, AVGR, FNCH, LIPO, HSDT, ARTL, THAR, and PEAR
Should you be buying Invitae stock or one of its competitors? The main competitors of Invitae include OpGen (OPGN), BioNexus Gene Lab (BGLC), SenesTech (SNES), Avinger (AVGR), Finch Therapeutics Group (FNCH), Lipella Pharmaceuticals (LIPO), Helius Medical Technologies (HSDT), Artelo Biosciences (ARTL), Tharimmune (THAR), and Pear Therapeutics (PEAR). These companies are all part of the "medical" sector.
Invitae (NYSE:NVTA) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
In the previous week, Invitae had 1 more articles in the media than OpGen. MarketBeat recorded 2 mentions for Invitae and 1 mentions for OpGen. Invitae's average media sentiment score of 0.28 beat OpGen's score of 0.00 indicating that Invitae is being referred to more favorably in the media.
Invitae has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, OpGen has a beta of -0.78, suggesting that its stock price is 178% less volatile than the S&P 500.
61.3% of Invitae shares are held by institutional investors. Comparatively, 13.1% of OpGen shares are held by institutional investors. 0.7% of Invitae shares are held by company insiders. Comparatively, 1.3% of OpGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Invitae currently has a consensus target price of $1.00, suggesting a potential upside of 5,782.35%. Given Invitae's higher possible upside, equities analysts clearly believe Invitae is more favorable than OpGen.
OpGen has lower revenue, but higher earnings than Invitae. OpGen is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.
Invitae received 150 more outperform votes than OpGen when rated by MarketBeat users. Likewise, 61.36% of users gave Invitae an outperform vote while only 56.58% of users gave OpGen an outperform vote.
Invitae has a net margin of -299.14% compared to OpGen's net margin of -852.18%. OpGen's return on equity of -316.30% beat Invitae's return on equity.
Summary
Invitae beats OpGen on 12 of the 17 factors compared between the two stocks.
Get Invitae News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools